Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924480 · ClinicalTrials.gov registry record · NA
Intravenous Lidocaine for Cystectomy Procedures
A NA study of Invasive Bladder Cancer, sponsored by CAMC Health System.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02924480: Completed NA study of Invasive Bladder Cancer, sponsored by CAMC Health System.
NCT02924480 is a NA study of Invasive Bladder Cancer that has completed, run by CAMC Health System. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02924480, a NA study of Invasive Bladder Cancer, has completed, sponsored by CAMC Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients scheduled for a cystectomy at Charleston Area Medical Center (CAMC) will be enrolled into a randomized, double blinded clinical trial to assess if postoperative pain and ileus are reduced by perioperative intravenous lidocaine infusion versus placebo. The hypothesis is that patients receiving the lidocaine infusion will experience better pain control and ileus resolution. It is believed that lidocaine patients will also have less opioid requirement, less mortality, a shorter length of stay, less nausea /vomiting, and fewer adverse events.
Primary Outcome
Use verbal analog score to assess patients pain and compare between study and control groups. This will determine if patients in the lidocaine study arm experience less pain than those in the placebo group.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Lidocaine
- PROCEDURE Cystectomy
Study Locations (1)
West Virginia
- Urology center of charleston - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2020-06-17 |
| Phase | NA |
What the finished NCT02924480 record still lists
NCT02924480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT02924480 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT02924480 about?
NCT02924480 is a clinical study titled "Intravenous Lidocaine for Cystectomy Procedures". Patients scheduled for a cystectomy at Charleston Area Medical Center (CAMC) will be enrolled into a randomized, double blinded clinical trial to assess if postoperative pain and ileus are reduced by perioperative intravenous lidocaine infusion versus placebo. The hypothesis is that patients receivi...
What is the current status of trial NCT02924480?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2016-10-12. Estimated completion is 2020-06-17.
What conditions does trial NCT02924480 study?
This clinical trial studies the following conditions: Invasive Bladder Cancer.
What interventions are being tested in trial NCT02924480?
The interventions under investigation include: Saline (DRUG), Lidocaine (DRUG), Cystectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02924480?
This trial is sponsored by CAMC Health System, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02924480 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02924480's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI